| 发明名称 | 1,3,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease | ||
| 摘要 | The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA. | ||
| 申请公布号 | US9611230(B2) | 申请公布日期 | 2017.04.04 |
| 申请号 | US200511577191 | 申请日期 | 2005.10.13 |
| 申请人 | PTC Therapeutics, Inc. | 发明人 | Almstead Neil G.;Chen Guangming;Karp Gary M.;Welch Ellen;Wilde Richard;Campbell Jeffrey A. |
| 分类号 | C07D271/10;C07D271/107;C07D251/24;C07D231/12;C07D233/64;C07D249/08;C07D261/08;C07D263/32;C07D271/06;C07D277/30;C07D285/12;C07D307/68;C07D333/24;C07D413/12;C07F9/653;C07D401/04;C07D403/04;C07D405/04;C07D409/04;C07D413/04 | 主分类号 | C07D271/10 |
| 代理机构 | Hoffmann & Baron, LLP | 代理人 | Hoffmann & Baron, LLP |
| 主权项 | 1. A compound of Formula 1-A: wherein: R3 is absent; W is selected from the group consisting of: wherein when W is selected from the group consisting of: then shown in Formula 1-A is in the meta or para position; and wherein when W is selected from the group consisting of then shown in Formula 1-A is in the meta position; and a pharmaceutically acceptable salt of said compound of Formula 1-A, wherein * indicates the only bond of attachment for W, and wherein said bond of attachment is a direct bond of attachment. | ||
| 地址 | South Plainfield NJ US | ||